Company: BIAF
Filing Date: 2025-05-05
Form Type: S-1/A
Source: 0001641172-25-008629
Chunk: 189

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-05
Form: S-1/A
Chunk 189
---
 the Placement Agent Warrants is included as an exhibit to this registration statement of which this prospectus forms a part.

| 90 |

Right of First Refusal

In addition, with certain exceptions, for a period of six months following the closing of this offering, if we decide to raise funds by means of a public offering (including “at the market offering” facility) the right to act as sole book-running manager, sole underwriter or sole placement agent for such financing.

Tail

We have also agreed to pay the Placement Agent a tail fee equal to both the cash and warrant compensation in this offering, if this offering is not consummated and any potential investor who was brought over-the-wall by the Placement Agent with respect to an offering other than a public offering or contacted by the Placement Agent with respect to a public offering during the term of its engagement, provides us with capital in any public or private offering or other financing or capital raising transaction during the twelve-month period following expiration or termination of our engagement with the Placement Agent. Notwithstanding anything to the contrary contained in the agreement with the Placement Agent, if the engagement of the Placement Agent is terminated for cause, the Placement Agent shall not have the right to receive any tail fee pursuant to FINRA Rule 5110(g)(5).

Determination of Offering Price

The public offering price per share (or Pre-Funded Warrant) and accompanying May 2025 Warrant we are offering and the exercise prices and other terms of the May 2025 Warrants were negotiated between us and the investors, in consultation with the Placement Agent based on the trading of our Common Stock prior to this offering, among other things. Other factors considered in determining the public offering prices of the securities we are offering and the exercise prices and other terms of the May 2025 Warrants include the history and prospects of our Company, the stage of development of our business, our business plans for the future and the extent to which they have been implemented, an assessment of our management, general conditions of the securities markets at the time of the offering and such other factors as were deemed relevant. The combined public offering price per share (or Pre-Funded Warrant) and warrants will be fixed for the duration of this offering.

Indemnification

We have agreed to indemnify the Placement Agent against certain liabilities, including certain liabilities arising under the Securities Act, or to contribute to payments that the Placement Agent may be required to make for these liabilities.

Regulation M

The Placement Agent may be deemed to be an under